PX1 Research has announced the release of new batches of Retatrutide and Tirzepatide research peptides, manufactured in USA cGMP-certified facilities and verified through rigorous HPLC batch verification protocols. This expansion of the company's dual-incretin peptide catalog underscores a commitment to quality, with every batch accompanied by Certificates of Analysis confirming purity ratings of 99% or above.
The production of these peptides under Current Good Manufacturing Practice (cGMP) standards is a significant differentiator in the research peptide market. cGMP certification encompasses strict facility conditions, equipment qualification, personnel training, and documentation practices, ensuring a traceable chain of production. For research institutions and procurement teams, domestic cGMP manufacturing offers compliance assurance and a level of documentation that supports data integrity in experimental settings. PX1 Research leverages over 16 years of peptide manufacturing expertise, which informs both formulation precision and quality control methodology.
Each batch of Retatrutide and Tirzepatide undergoes a seven-stage testing protocol prior to shipment, with HPLC (high-performance liquid chromatography) as the analytical backbone. HPLC separates peptide compounds within a sample to quantify purity with high resolution, and applying this at the batch level—rather than as a periodic audit—ensures that every individual shipment carries documentation reflecting its specific test results. The seven-stage framework extends beyond chromatographic purity to include endotoxin detection, amino acid sequence integrity verification, and mass confirmation through spectrometric analysis. The outcome is a batch-specific Certificate of Analysis that researchers can reference against their own quality requirements.
Both compounds hold significant positions in metabolic and endocrine research. Tirzepatide functions as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Retatrutide extends this mechanism as a triple agonist, also engaging the glucagon receptor. The structural complexity of these molecules demands high manufacturing precision, as minor sequence deviations can alter receptor binding profiles. PX1 Research's unified manufacturing and verification framework allows research teams to source both peptides with comparable documentation standards, a practical advantage for studies comparing the two molecules or running parallel arms.
The newly released batches are available for procurement through PX1 Research's catalog, with the Retatrutide offering accessible at px1research.com and the Tirzepatide offering at px1research.com. Certificates of Analysis corresponding to current batch numbers are provided alongside each product listing, facilitating informed purchasing decisions.
